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Abstract
Toll-like receptors (TLR) represent the best characterized receptor family transducing innate immune responses, the first line
of defense against microbial invaders. This study was designed to investigate whether responses through TLR inhibit HIV-1
replication in its primary target cells. Primary human macrophages and lymphocytes from several different donors and HIV-1
infection in tissue culture were used exclusively in this work. We report that ligands of three different TLR: LPS, R848, and
double stranded RNA, induce a common antiviral response in macrophages as assayed by measurement of HIV-1 p24
protein, gag DNA, and entry into cells. HIV-1 infection is arrested after efficient entry but prior to reverse transcription. TLR-
ligand activated cells secrete antiviral factors that induce a similar restriction. HIV-1 infection of lymphocytes is not affected
by exposure to TLR ligands or to antiviral factors secreted by activated macrophages. TBK1, but neither NF-kB nor JAK-STAT
activity, is required in macrophages to mount this antiviral response; the combination of p38 MAPK and JNK are partially
required for induction of antiviral activity. Based on transcriptional induction and inhibition, the TLR-linked antiviral activity
is different from APOBEC3 A or G, interferon-b, NAMPT, or p21
Cip1. The cell-type specificity, site of action, and requirement
for signaling intermediates suggest that the TLR-linked antiviral activity is novel.
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Introduction
Macrophages perform dual roles during HIV-1 infection [1].
Like CD4-bearing T lymphocytes, they are a prominent target for
virus replication. As major effectors of innate immunity, they have
the potential to mount antiviral responses within hours of systemic
infection. The salience of such immediate reaction to HIV-1
infection has been demonstrated in the intense cytokine cascade
detected in the plasma of HIV-1 infected people that precedes the
peak of viremia seen early after virus transmission [2].
Innate immune responses can be initiated by triggering pattern
recognition receptors (PRR) that bind classes of molecules
expressed by pathogens [3,4]. The first family of PRR defined in
mammals is the Toll-like receptor (TLR) group that comprises
both plasma membrane and intracellular receptors for bacterial or
viral lipids, proteins, or nucleic acids. TLR expression is cell type
specific with dendritic cells and macrophages expressing all TLR.
TLR ligation activates distinct signal transduction pathways
resulting in transcription of many effector molecules including
TNF-a, IL-6, and type I interferons [4].
With diverse TLR types and diverse ligands, it is not surprising
that innate immune responses through TLR have been observed
to have several different effects upon HIV-1 replication. More
than 20 years ago it was recognized that the commonly used
macrophage activator and TLR4 ligand LPS reduces HIV-1
replication in primary human macrophages [5]. The basis of this
inhibition has been attributed to impaired viral entry by down-
modulation of CCR5 [6] or by an unknown soluble factor
inhibiting X4-tropic virus entry [7]. Prothymosin-a, also by
ligation of TLR4, was shown to induce type I interferon
production by macrophages and inhibit HIV-1 replication after
viral DNA integration [8]. Mycobacterium tuberculosis, which
contains ligands for TLR2 and TLR4, has been shown to induce a
post-entry, pre-reverse transcription block in HIV-1 replication in
macrophages [9], although earlier studies had shown that
mycobacterium infection of macrophages enhanced HIV-1
replication [10]. One study investigating several TLR responses
found that the TLR5 ligand, flagellin, enhanced both R5 and X4
HIV-1 replication while a TLR9 ligand, M362, inhibited
replication by both viruses in lymphoid tissue blocks [11]. Ligation
of TLR3 induced multiple antiviral activities in primary human
macrophages and blocked HIV-1 replication [12].
We have a long-standing interest in HIV-1 replication in
macrophages and its control. The present study was designed to
determine how innate immune responses affect HIV-1 replication
by investigating common effects of different TLR ligands upon
HIV-1 infection of monocyte-derived macrophages (MDM). We
found that ligation of TLR3, 4, or 7/8 on MDM blocked R5 HIV-
1 infection of MDM but not of peripheral blood lymphocytes.
After TLR activation, MDM secreted a soluble factor that
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24193inhibited HIV-1 infection of untreated MDM. Infection was
arrested after virus entry into MDM but before reverse
transcription. Using pharmacological inhibitors we found that
TLR activation to this antiviral state did not require NFkB, JAK,
JNK, or but did require TBK1. The antiviral state triggered by
TLR activation could be distinguished from the induction of Type
I interferon, ABOBEC3G, p21
Cip1, and NAMPT. Taken together
our results indicate that TLR activation of human MDM induces
the production of a potentially novel antiviral activity blocking
HIV-1 infection following viral internalization.
Results
For an overview of the effects of TLR-ligation on HIV-1
infection of MDM, cells from two different donors were treated
with LPS, a TLR4 ligand, at the time of infection by ADA and
either washed out with virus or replaced after washing and
maintained during one week culture. HIV-1 replication was
monitored by measurement of extracellular p24 one week after
infection during the exponential increase in p24 production we
timed during studies of MDM infection kinetics [13] (Fig. 1). With
both transient and maintained exposure, LPS blocked ADA
replication in macrophages more than 100-fold. To determine
whether this anti-HIV-1 response restricts only the HIV-1 strain
ADA, we tested the sensitivity of other R5 HIV-1 strains to
inhibition by transient exposure to LPS. MDM were treated with
LPS and infected either with ADA, B.aL, or YU-2 and infection
was monitored by p24 expression (Fig. 2). MDM susceptibility to
each virus was greatly inhibited by exposure to LPS.
To determine whether this antiviral effect was common to
different TLR responses, the experiment was repeated with MDM
that were treated in dose response either with LPS; R848, a
synthetic TLR7/8 ligand; or double stranded RNA, a TLR 3
ligand; during ADA infection, each TLR ligand was washed out
with virus for transient exposure. Virus replication was monitored
by measurement of extracellular p24 four days after infection
(Fig. 3). The innate immune response through TLR3, 4, or 7/8
each controlled HIV-1 infection of primary human macrophages.
In contrast, neither of the macrophage activators, TNF-a nor
supernatants of primary human astrocytes, significantly affected
HIV-1 replication in MDM (not shown) [14,15].
A recent study shows that HIV-1 infection of lymphoid tissue is
affected differently by different TLR ligands [11], so we
investigated whether HIV-1 infection of purified human periph-
eral blood lymphocytes (PBL) is affected by exposure to ligands of
TLR3, 4, or 7/8. Mitogen activated PBL were treated with
dsRNA, LPS, or R848 and then infected with X4 HIV-1/NL4-3
and infection was monitored by measurement of extracellular p24
after one week (Fig. 4). In contrast to MDM infection, PBL
infection was only minimally affected by any TLR ligand
suggesting that the response is cell-type specific.
Endogenous antiviral activities act at several phases of the HIV-
1 life cycle [16] so we investigated at what stage of HIV-1
replication the TLR response of MDM exerts its effects. Cells were
treated either with LPS, R848, or dsRNA; infected with ADA and
after 24 h, during the first round of reverse transcription in
infected MDM [13,17], viral gag DNA was measured by real-time
PCR; standardizing DNA by amplification of b globin (Fig. 5). As
observed with measurement of infection by p24 production, MDM
responded to different TLR ligands in the same way, here by
arresting ADA infection prior to viral DNA synthesis. Since HIV-1
infection is arrested before reverse transcription potential sites of
TLR ligand induced inhibition later in the virus life cycle are
rendered moot.
To further define the site of infection arrest, we employed an
assay of HIV-1-cell fusion in which Vpr-b lactamase (Vpr-BLaM)
is encapsidated in HIV-1 virions and virus entry permits cleavage
of a BLaM substrate loaded into cell cytoplasm, cleavage is scored
by a fluorescence shift from green to blue [18] (Fig. 6). MDM were
treated either with LPS or with TAK779, a CCR5 antagonist,
then infected with YU-2 containing Vpr-BLaM, and then assayed
for fusion (Fig. 6), or were cultured in parallel to measure p24
levels. MDM allowed efficient entry of YU-2 that was completely
sensitive to neutralization by TAK779. In sharp contrast to their
block on viral DNA synthesis (Fig. 5), LPS-treated MDM were
Figure 1. LPS induces an anti-HIV-1 response in MDM. MDM
from two different donors were treated with vehicle or LPS prior to and
during infection with ADA. LPS was washed out with virus (wash) or was
replaced for one week culture. Cell supernatants were then harvested
for measurement of HIV-1 p24. N (number of experiments with cells
from different donors) .4.
doi:10.1371/journal.pone.0024193.g001
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inhibitors potentially induced by LPS in the antiviral effect
observed. MDM treated transiently with LPS restricted YU-2
infection with control cells producing 47 ng p24 per ml and LPS-
treated cells producing less than 2 ng p24 per ml.. Results shown
in Figures 5 and 6 indicate that LPS treated MDM arrest HIV-1
infection after efficient binding, fusion, and entry but prior to
reverse transcription.
TLR-stimulation activates secretion of several physiologically
active factors, so we tested the supernatants of MDM treated with
LPS for various times to determine whether they contain an
Figure 2. LPS activated MDM resist infection by three different
strains of HIV-1. MDM were treated with LPS or vehicle and infected
with the virus indicated, LPS was washed out with virus. After one week
of culture, cell supernatants were harvested for measurement of HIV-1
p24. N=2.
doi:10.1371/journal.pone.0024193.g002
Figure 3. Three different TLR ligands induce an anti-HIV-1
response in MDM. MDM were treated with either vehicle, LPS, R848,
or dsRNA at the doses indicated. Cells were treated and infected as
described in Fig. 1 with ligands washed out with virus. N=3.
doi:10.1371/journal.pone.0024193.g003
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washed extensively, and then supernatants were collected over
several hours. For infection MDM were treated with supernatants
during exposure to ADA and extracellular p24 was measured four
days after infection. LPS-treated MDM secrete an anti-HIV-1
factor(s) that largely prevents infection of MDM; its activity is
present within one hour of LPS stimulation and persists for several
hours thereafter (Fig. 7). To begin to characterize the TLR-
induced antiviral factors, we tested their ability to block HIV-1
infection of PBL that themselves do not mount antiviral responses
by exposure to TLR ligands (Fig. 4). Supernatants of control
MDM or LPS-activated MDM known to block HIV-1 infection of
MDM were tested for their effects upon HIV-1 infection of PBL
(Fig. 8). It is striking that PBL retained full susceptibility to X4
NL4-3. The two-fold decrease in PBL susceptibility to R5 ADA
after exposure to supernatants of both control and activated MDM
may indicate the presence of similar levels of ß–chemokines that
inhibit R5 HIV-1 entry [19].
TLR responses can utilize multiple signaling pathways [20]. To
identify key elements leading to the production of inhibitors of
HIV -1 infection, we activated MDM with TLR ligands in the
presence of inhibitors of various signaling intermediates and
assayed their susceptibility to HIV-1 infection. Given its relevance
to TLR responses, the role of NF-kB activation in antiviral factor
induction was first tested, using CAPE that interferes with the
binding of NF-kB to DNA and PS-1145, which inhibits
phosphorylation of I-kB. Pilot electrophoretic mobility shift studies
confirmed that CAPE and PS-1145 inhibited LPS-induced
activation of NF-kB in MDM under conditions used here (not
shown). To test the role of NF-kB in LPS-induced antiviral
activity, MDM were pretreated with inhibitors for 1 h, activated
with different TLR ligands in the presence of inhibitors, infected
by ADA, and then cultured for four days, virus replication was
monitored by p24 production (Fig. 9A). Neither inhibitor of NF-
kB activation had an effect upon the complete HIV-1 inhibition
induced by LPS, R848, or dsRNA. However both CAPE and PS-
1145 themselves inhibited ADA replication two to three fold and
the mechanism of this inhibition is under investigation. Testing
supernatants of similarly activated MDM for their effects upon
ADA replication prior to reverse transcription confirmed that
induction of an antiviral state was not dependent upon NF-kB
(Fig. 9B).
Using the same logic to identify intermediates in control of gene
expression leading to an antiviral state, we investigated the
requirements for p38 MAPK and JNK, kinases required for the
Figure 4. PBL fail to respond to TLR by an anti-HIV-1 response.
Mitogen activated PBL were treated with TLR ligands as described in
Materials and Methods prior to and during exposure to NL4-3. Virus and
TLR ligands were washed out, cells returned to culture for one week
prior to collection of supernatants for measurement of HIV-1 p24. N=2.
doi:10.1371/journal.pone.0024193.g004
Figure 5. TLR ligand induced anti-HIV-1 response blocks
infection prior to reverse transcription. MDM were treated with
TLR ligands as described in Materials and Methods prior to and during
exposure to ADA. Virus and TLR ligands were washed out, cells returned
to culture for 24 h prior to collection of cells for measurement of HIV-1
gag DNA by real-time PCR; means and standard deviations are plotted,
** p,0.005 in Student’s t test of virus burdens between vehicle and TLR
treated cells. N=4.
doi:10.1371/journal.pone.0024193.g005
Figure 6. LPS activated MDM permit efficient HIV-1 entry. MDM
were treated with vehicle (B) LPS (C), or TAK-779 (D), infected with YU-2-
Blam-Vpr, and subjected to flow cytometry as described in Materials
and Methods. Uninfected cells (A) serve as negative controls. N=6.
doi:10.1371/journal.pone.0024193.g006
Immunity to HIV-1 through Toll-Like Receptors
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effects upon the HIV-1 resistance in MDM. We scored HIV-1
replication and inhibition by the measurement of viral DNA
(Fig. 10A). Tested alone, neither the JNK MAPK inhibitor (JNK-I)
nor the p38 MAPK inhibitor, SB203580, affected the LPS
antiviral response, however when the inhibitors were tested
together there was a partial relief in the LPS block to HIV-1
infection. When tested in the absence of TLR ligands, we found no
effect of the JNK-I and SB203580 upon ADA infection (not
shown). To confirm the requirement for these kinases in TLR
responses, we tested the effects of R848 and dsRNA as well as LPS
for effects upon HIV-1 replication in the presence of SB203580
and the JNK-I (Fig. 10B). Anti-HIV-1 responses to any of the three
TLR ligands were partially reversed by blocking the combination
of these kinase cascades. Similarly, supernatants of MDM
activated by LPS in the presence of SB203580 and the JNK-I
contain less antiviral activity (Fig. 10C). This observation is
consistent with a requirement for p38 MAPK and JNK in the
response to LPS producing an antiviral factor or in the action of
the antiviral factor in blocking HIV-1 replication. To distinguish
between these possibilities, we separated LPS activation of MDM
from test of antiviral activity during HIV-1 infection. MDM were
activated with vehicle or LPS in the presence or absence of
SB203580 and the JNK-I and their supernatants were harvested to
assay antiviral activity. Antiviral activity was tested during ADA
infection of MDM, conducted in the presence or absence of
SB203580 and the JNK inhibitor (Fig. 10C). The combination of
SB203580 and JNK-I reduced the level of antiviral activity in
supernatant of LPS treated cells. However, that the action of the
antiviral factors in supernatants of LPS-activated cells is
independent of both p38 MAPK and JNK, since MDM treated
with LPS supernatants were resistant to ADA infection, despite
being infected and cultured in the presence of the kinase inhibitors
(Fig. 10C).
The TBK1/IRF-3/interferon-b (IFN-b) signaling pathway is
well documented for its critical roles in mediating TLR-induced
antiviral responses [21], so we tested its involvement in the TLR
induced anti-HIV-1 response described here. The antiviral
response to LPS was reversed in MDM treated with LPS and the
TBK1 inhibitor, BX-795 (Fig. 11A). To test the role of TBK1 in
the LPS-induced secretion of antiviral factors, supernatants were
collected from MDM treated with LPS, different doses of BX-795,
or both and then used for treatment of MDM during ADA
infection (Fig 11B). BX-795 highly significantly reduced the level
of antiviral activity in LPS supernatants in dose response
(p,0.005), although even at the highest dose of the BX-795,
antiviral activity was detected. Note that BX-795 had no effect
upon ADA replication, as shown in BX-795 dose response
conducted in the presence of control MDM supernatant. To
determine whether TBK1 is required for the response to LPS in
contrast to the antiviral activity against HIV-1 we again separated
these two phases of cellular activity. To test the production of
antiviral factors, MDM were treated with vehicle or LPS in the
presence or absence of BX-795 and their supernatants were
harvested. Antiviral activity in supernatants was tested during
ADA infection of MDM conducted in the presence or absence of
Figure 7. LPS activated MDM secrete anti-HIV-1 factor (s). MDM
were treated with LPS for 10 min or left untreated, washed, and then
supernatants harvested at the times shown. Supernatants were then
applied to MDM prior to ADA infection. Infected MDM were cultured
four days prior to collection of supernatants for measurement of p24.
N.3.
doi:10.1371/journal.pone.0024193.g007
Figure 8. HIV-1 infection of PBL is resistant to LPS-induced
antiviral factor. Supernatants of MDM activated by LPS were
harvested after 4 h and applied to PBL prior to infection by ADA (A)
or NL4-3 (B). Infected PBL were cultured for one week prior to collection
of supernatants for measurement of p24. N=2.
doi:10.1371/journal.pone.0024193.g008
Immunity to HIV-1 through Toll-Like Receptors
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e24193BX-795 (Fig. 11C). BX-795 blocked the LPS induced production
of antiviral factors by MDM. However when antiviral factors
induced in MDM by LPS were tested during infection in the
presence of BX-795, they largely maintained activity and inhibited
HIV-1 replication, indicating that TBK1 is not essential for their
antiviral function (Fig 11C).
The requirement for TBK1 for LPS-induction of anti-HIV-1
factors is consistent with the possibility that IFN-b is responsible
for some or all of the antiviral activity [21]. To evaluate this
proposition, we first tested whether IFN-b was produced in
response to LPS and whether its induction was sensitive to BX-
795, IFN-b was measured by Elisa (Fig. 12A). We found that LPS
induced 207 pg IFN-b per ml, using this assay equivalent to less
than 100 inhibitory units (IU). Parallel Elisa failed to detect IFN-
a with a limit of detection of 12 pg per ml. The induction of IFN-
b was sensitive to inhibition by BX-795, consistent with a role for
IFN-b in the antiviral state described here. Because IFN-b
induces a large suite of antiviral activities through JAK/STAT
signaling, we tested the requirement for JAK/STAT in mediation
of anti-HIV-1 factor activity induced by LPS. We conducted a
dose response of recombinant IFN-b in MDM and observed that
1000 IU were required for optimal STAT-1 phosphorylation (not
shown). The supernatant from LPS-activated MDM was
compared to 1000 IU recombinant IFN-b for the ability to
inhibit ADA infection of MDM in the presence of graded doses of
JAK inhibitor (JAK-I) (Fig. 12B). Both supernatant of LPS-
activated MDM and recombinant IFN-b significantly inhibited
HIV-1 infection prior to viral DNA synthesis (p,0.005), note that
the effective dose of IFN-b was more than 10 times its
concentration in the activated MDM supernatant. The antiviral
activity of IFN-b was significantly reduced by the JAK-I in dose
response, with no significant inhibition of HIV-1 by IFN-b
observed in the presence of 5 mM JAK-I. In striking contrast, the
antiviral activity produced by LPS-activated MDM maintained
highly significant inhibition (p, 0.001-0.02) at all doses of the
JAK-I tested. However, induction by LPS may involve JAK/
STAT signaling to produce IFN-b or other antiviral factors. To
test this possibility we investigated the sensitivity of MDM
activation by LPS to JAK-I. MDM were activated by LPS in the
presence of graded doses of JAK-I and their supernatants were
collected. The supernatants were then tested for their antiviral
activity (Fig. 12C). Inhibition of JAK/STAT signaling did not
affect the extent of antiviral activity produced by LPS-activated
MDM with significant inhibitory activity present in supernatants
(p,0.005) produced at all doses of the JAK-I. These findings
indicate that the TLR ligand-induced antiviral activity described
here is different from IFN-b and from other factors requiring
JAK/STAT signaling in their induction.
Given the difference in their effects upon antiviral factor
production, BX-795 and JAK-I provide a tool to identify the active
factor. Expression of the TLR-linked antiviral factor should be
induced in MDM by LPS in the presence of JAK-I, but its LPS-
induction should be reduced by treatment of cells with BX-795.
We investigated five defined anti-HIV-1 factors that can be
expressed in macrophages [16,22] for their induction by LPS and
the sensitivity of this induction to inhibition by BX-795 or JAK-I;
transcripts were measured over four hours induction using real-
time PCR (Fig. 13). APOBEC 3A, APOBEC 3G, IFN-b,
NAMPT, and p21
Cip1 were each induced in MDM by LPS to
varying degrees from 4000-fold for IFN-b to roughly 5-fold for
APOBEC 3G. The expression of NAMPT was largely resistant to
the signaling inhibitors, the expression of the four other transcripts
was sensitive to both inhibitors. These results indicate that the
antiviral activity studied here that requires TBK1 but is
independent of JAK/STAT signaling is different from APOBEC
3A, APOBEC 3G, IFN-b, NAMPT, and p21
Cip1 because of the
signaling requirements for their expression following LPS
activation.
Discussion
We find that upon triggering any of three TLR, MDM mount
an innate immune response that inhibits HIV-1 infection, they
secrete factor(s) that induce a similar antiviral state in untreated
MDM. Lymphocytes neither express nor respond to this antiviral
activity. TLR-activated MDM permit HIV-1 entry but block virus
replication prior to reverse transcription. The cell-type specificity,
site of action, and requirement for signaling intermediates suggest
that the antiviral activity observed is novel.
Figure 9. NF-kB is dispensable for the anti-HIV-1 response
induced by three different TLR ligands. (A) MDM were activated
and infected by ADA as described in Fig 3 in the presence of CAPE, PS-
1145, or vehicle and were cultured four days prior to collection of
supernatants for measurement of p24. N=2. (B). MDM were treated
with the inhibitors shown and LPS and then supernatants were
harvested; supernatants were then applied to MDM during ADA
infection as described in Materials and Methods; infected cells were
harvested after 24 h for measurement of HIV-1 DNA, means and
standard deviations are plotted. N=3. ** p,0.005 in Student’s t test of
virus burdens between vehicle and LPS treated cells.
doi:10.1371/journal.pone.0024193.g009
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cell donors, triggered by multiple TLR ligands, and active against
multiple HIV-1 strains. Activated MDM restrict HIV-1 replication
and they also secrete antiviral activity. Because the antiviral
activity can be detected in supernatants of MDM within an hour
of their exposure to TLR ligands, it is possible that an antiviral
factor is secreted, internalizes in infected cells, and then arrests
HIV-1 replication after virus entry. In contrast, PBL do not
respond to TLR ligands by inhibition of HIV-1 infection and
MDM-derived antiviral factors do not affect HIV-1 infection of
PBL. This suggests that the antiviral factor described here is
different from previously reported antiviral factors APOBEC 3G,
b-chemokines, and SLPI that inhibit HIV-1 replication in PBL
[22,23].
Activated macrophages, including macrophages activated by
IFN-b[24] or dsRNA [12], produce b-chemokines [25] that
antagonize R5 HIV-1 binding to CCR5 and block infection at
entry [26]. LPS-activated MDM also have been reported to
directly down-regulate CCR5 expression and acquire resistance to
R5 HIV-1 entry [6]. However we find that MDM activated by
LPS allow efficient HIV-1 entry, placing the activity of the
antiviral factor post-entry but prior to reverse transcription.
p21
Cip1 expression by macrophages has been found to have an
antiviral effect similar to ours in some studies [27] but to enhance
HIV-1 infection of macrophages in other studies [28]. The
antiviral activity investigated here can be distinguished from
p21
Cip1 because the induction of p21
Cip1by LPS is sensitive to
inhibition by JAK-I. (Fig. 13).
To identify the route of induction of antiviral activity by MDM,
we investigated the requirement for certain intermediates in TLR
signaling. Induction of antiviral activity here requires TBK1 and
can utilize the combined effects of p38 and JNK MAPK. In
contrast, it was striking that both the NF-kB and the JAK/STAT
pathways that are prominent in TLR response networks were
dispensable for the anti-HIV-1 activity induced in MDM. On that
basis, b-chemokines, some antiviral cytokines, and IFN-related
genes that can affect HIV-1 replication [20,27] are not likely to be
responsible for the HIV-1 inhibition seen under our conditions.
Similarly, we found that LPS-induction of expression of previously
described antiviral factors APOBEC 3A, APOBEC 3G, IFN-b,
p21
Cip1 [16] is inconsistent with the anti-HIV-1 activity here
because their expression requires both TBK-1 and JAK/STAT as
noted above, while NAMPT [22] can be ruled out as the mediator
observed here because its expression requires neither TBK-1 nor
JAK/STAT. Taken together, our findings suggest that there is an
unidentified factor produced in response to TLR ligands that can
arrest HIV-1 infection of macrophages after virus entry and before
reverse transcription.
Responses to TLR ligands have been described to underlie
HIV-1 or SIV pathogenesis [11,29,30] or to provide some
protection against HIV-1 replication [31]. The ligands examined
here may be encountered during HIV-1 infection of human
beings: LPS through microbial translocation from the gut [29],
single stranded RNA in the viral genome, and dsRNA as an
intermediate during reverse transcription. We speculate that the
response mounted by MDM to TLR ligands may contribute to
HIV-1 control, particularly in tissues where HIV-1 predominantly
replicates in macrophages like the brain or the lung. Definition of
the antiviral factor mediating protection may provide an
additional approach to control or prevent HIV-1 spread.
Figure 10. The combined effects of p38 and JNK MAPK are
partially required for the anti-HIV-1 response induced by three
different TLR ligands. Panel A. MDM were activated by LPS and
infected by ADA in the presence of SB203580, JNK-I, both inhibitors, or
vehicle. N=3. Panel B. MDM were activated by LPS, R848, or dsRNA and
infected by ADA in the presence of SB203580 and JNK-I or vehicle.
N=2. Panel C. MDM were activated by LPS in the presence of vehicle or
SB203580 and JNK-I (LPS + SB203580+ JNK-I supt, grey bar).
Supernatants were collected and applied to fresh MDM that were
infected by ADA in the presence of vehicle or SB203580 and JNK-I
(ADA+ SB203580+JNK-I, grey striped bar). N=3. All infected cells were
harvested after 24 h for measurement of HIV-1 DNA, means and
standard deviations are plotted. * p,0.05, ** p,0.005, *** p ,0.0005 in
Student’s t test of virus burdens infected cell systems indicated.
doi:10.1371/journal.pone.0024193.g010
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Ethics statement
Healthy HIV-1 seronegative blood donors signed informed
consent forms that were approved by the University of Nebraska
Medical Center Institutional Review Board where blood was
collected, cells separated by centrifugal elutriation, and then
transferred for use in these studies for a fee. The studies reported
here using human peripheral blood monocytes and lymphocytes
were granted exempt status by the St. Luke’s-Roosevelt Institu-
tional Review Board under qualifications listed in section 45.101
(b) (4).
Reagents
Lipopolysaccharide (LPS) from Escherichia coli 0127:B8 and
PS-1145 were purchased from Sigma. Polyinosinic acid N
polycytidylic acid, sodium salt (dsRNA), CAPE, and JAK inhibitor
I were purchased from Calbiochem. R848 was purchased from
Invivogen. BX795 was purchased from Fisher Scientific. The p38
MAPK inhibitor, SB203580, and JNK MAPK inhibitor were
purchased from EMD Chemicals. Recombinant human IFN-b
was purchased from R & D Systems. Unless otherwise described,
the following doses were used: 100 ng/ml for LPS, 25 mg/ml for
dsRNA, 5 mg/ml for R848, 20 mM for PS-1145, 25 mg/ml for
CAPE, 20 mM for SB203580, 10 mM for JNK inhibitor, 5 mM for
BX795, 2 mM for JAK inhibitor, and 1000 IU of IFN-b.
Cell culture
Human peripheral blood monocytes and peripheral blood
lymphocytes were isolated by centrifugal elutriation from blood of
more than 20 HIV-1-negative, healthy donors. Monocytes were
differentiated to macrophages by culture in DMEM (10
6 cells/ml)
containing 10% human serum and 10% conditioned supernatant
of Giant Cell Tumor cells (TIB-223
TM, ATCC) for 6 days.
Floating cells were then washed away and attached macrophages
were cultured in DMEM with 10% fetal bovine serum (FBS)
overnight before being used for experiments. Under these
conditions, untreated MDM were 93% viable, cells treated with
LPS or inhibitors were 90-93% viable with the exception of CAPE
treated cells at 72% viable and BX795 at 85% viable as
determined by assay of lactate dehydrogenase release using a kit
purchased from Promega and conducted according to the
manufacturer’s instructions. PBL were cultured in RPMI medium
with 10% FBS in presence of PHA (5 mg/ml) and IL-2 (1 ng/ml)
for 2 days. Activated PBL were then washed and re-suspended in
RPMI with 10% FBS and IL-2 (1 ng/ml) before being used for
experiments.
Preparation of HIV-1 stocks
ADA and B.aL were prepared by infecting MDM, NL4-3 was
prepared by infecting CEM-SS cells obtained from the AIDS
Research Reagent Repository. From day 5 to day 13 after
infection, conditioned supernatant was collected every two days.
Supernatant was then centrifuged for 20 minutes at 3900 rpm at
4uC in Eppendorf Centrifuge 5810R to remove dead cells and cell
debris. To concentrate the virus, cleaned supernatant was
centrifuged again for 2 hours at 14000 rpm at 4uC in Beckman
Coulter centrifuge Avanti J-E. Virus pellet was re-suspended in
PBS (1:100 of original volume), snap-frozen, and stored at 280uC.
Virus titer was determined by HIV-1 p24 concentration by Elisa.
Figure 11. TBK1 is required for the anti-HIV-1 response
induced by LPS. (A) MDM were activated by LPS and infected by
ADA in the presence of BX-795 or vehicle. N=3. (B) MDM were activated
by LPS in the presence of vehicle or indicated concentrations of BX-795.
Supernatants were collected and applied to fresh MDM that were
infected by ADA in the presence of vehicle or BX-795. N=2. (C) MDM
were activated by LPS in the presence of vehicle or BX-795 (LPS + BX-
795 supt, grey bar). Supernatants were collected and applied to fresh
MDM that were infected by ADA in the presence of vehicle or BX-795
(ADA+ BX-795, grey striped bar). N.3. All infected cells were harvested
after 24 h for measurement of HIV-1 DNA, means and standard
deviations are plotted. * p,0.05, ** p,0.005, *** p,0.0005 in Student’s
t test comparing virus burdens in the infected cell systems indicated.
doi:10.1371/journal.pone.0024193.g011
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293 T cells using calcium phosphate. For Yu-2/BLaM-Vpr virus,
pCMV-BLaM-Vpr (kindly provided by Dr. W. Greene, Gladstone
Institute of Virology and Immunology, UCSF) and pAdVAntage
(Promega) vectors were co-transfected together with pUC19-YU-
2. Conditioned supernatant was collected on day 2 and day 3 after
transfection. Virus was then concentrated as described above. All
virus stocks were screened for mycoplasma and found to be
negative.
HIV-1 infection
For viruses prepared by direct infection and transfection, the
doses of infection used were 0.05 pg p24/cell and 0.2 pg p24/cell,
respectively. Cells were cultured with indicated dose of virus at
37uC, 5% CO2 for 1 hour. Supernatant was removed and the cells
were washed once with PBS and continued to be cultured in
appropriate medium.
MDM supernatant transfer
MDM were cultured in presence of TLR ligands at 37uC, 5%
CO2 for 10 minutes. Cells were then washed with cold PBS three
times and returned to culture in fresh DMEM with 10% FBS as
indicated. In experiments where cells were treated with signaling
inhibitors before TLR ligation, inhibitors were replaced after
washing. Conditioned supernatant was then collected which
contained signaling inhibitors. To assay antiviral activity in
supernatants, culture medium of untreated cells was removed
and replaced by the test supernatant and HIV-1, as indicated.
Unless otherwise stated, cells were washed after infection and the
same conditioned supernatant, was added back to cultures.
ELISA
To determine extracellular HIV-1 p24 concentration, superna-
tant from infected cells was collected as indicated and tested by
ELISA using a kit from PerkinElmer. To determine extracellular
IFN-b concentration, supernatant was collected 4 hours after LPS
stimulation and tested by ELISA using a kit obtained from
Interferonsource.
Real-time PCR analysis of HIV-1 DNA
DNA from infected cells was prepared using DNAzol reagent
(Invitrogen) following manufacturer’s instructions. Real time PCR
to amplify HIV-1 gag was conducted in ABI 7500 Real Time PCR
System using primers for gag 59-TGGGACCACAGGCTACAC-
TAGA-39 and 59-CAGCCAAAACTCTTGCTTTATGG-39 pur-
chased from Invitrogen and probe 59-TGATGACAGCATGC-
CAGGGAGTGG-39 purchased from Applied Biosystems (ABI).
For quantitation of gag a standard curve was conducted using
HIV-1 plasmid DNA. DNA input was standardized by amplifi-
cation of human b2globin in parallel using primer and probe set
was from ABI: Hs00758889_s1.
Fluorescence Resonance Energy Transfer-based HIV-1 fusion
assay (FRET assay) MDM were cultured in 12-well plates
(10
6 cells/well) in 1 ml of DMEM with 10% FBS. After being
treated with LPS or TAK-779, cells were cultured with YU-2-
BLaM-vpr virus (0.2 pg p24/cell) at 37uC, 5% of CO2 for 2 hours.
Supernatant was then removed and cells were washed twice with
PBS and once with CO2-independent medium. 66 CCF2-AM
solution was prepared using BLaM Loading Solutions with CCF2-
AM substrate (K1085, from Invitrogen) following manufacturer’s
instructions. 40 mlo f6 6CCF2-AM solution was then added into
each well of cell culture (in 200 mlo fC O 2-independent medium).
Cells were then incubated at room temperature in the dark for
Figure 12. IFN-b is dispensable for the anti-HIV-1 response
induced by LPS. (A) MDM were activated by LPS in the presence of
vehicle or BX-795, supernatants were collected for the measurement of
IFN-b. N=2. (B) MDM were infected by ADA at the indicated
concentrations of JAK-I in the presence of vehicle, supernatants of LPS-
activated cells, or recombinant IFN-b. N=2. (C) MDM were activated by
LPS in the presence of vehicle or indicated concentrations of JAK-I and
their supernatants were collected and applied to fresh MDM that were
infected by ADA. N=3. All infected cells were harvested after 24 h for
measurement of HIV-1 DNA, means and standard deviations are plotted.
doi:10.1371/journal.pone.0024193.g012
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(2.5 mM of probenecid and 10% FBS in CO2 -independent
medium), and continued to be cultured in development medium
(1 ml/well) at room temperature in the dark for 16 hours.
Development was stopped by removing development medium and
washing cells with PBS. Cells were then collected by cell scraper
(Fisher Scientific) and re-suspended thoroughly in PBS followed by
fixation with 1.2% of paraformaldehyde for 2 hours at 4uC.
Fusion of virion was analyzed by flow cytometry detection of
fluorescence emission at 520 nm and 447 nm with BD LSRII
Flow Cytometer. Data were analyzed with Flowjo Software.
Real-time PCR analysis of mRNA expression
RNA from treated cells was prepared using TRIzol reagent
(Invitrogen) and then purified using RNeasy Mini Kit (Qiagen)
following manufacturer’s instructions. Revere transcription was
then carried using SuperScriptTM First-Strand Synthesis System
for RT-PCR (Invitrogen). cDNA was then subjected to real-time
PCRanalysisof mRNAexpressionbya DCtmethodwithABI7500
Real Time PCR System. For IFN-b, primers were synthesized from
Invitrogen: 59-GCCAGGAGGTTCTCAACAAT-39 and 59-
CTTTGCTATTTTCAGACAAGATTCA-39; and probe was
from Roche Universal Probe Library No. 20. For the other genes,
primer and probe set for TaqMan Gene Expression Assays from
ABI were used: cyclin-dependent kinase inhibitor 1A (p21,
Hs00355782_m1), apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3A (APOBEC 3A, Hs00377444_m1),
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like
3G (APOBEC 3G, Hs00222415_m1), and nicotinamide phosphor-
ibosyl-transferase (NAMPT, Hs00237184_m1). GAPDH (ABI
primer and probe set, 4352934E) was used as an endogenous
standard.
Replicas and statistics
Every experiment was performed independently in cells from
two or more donors. The number of donors employed is noted in
each figure legend as N. As indicated, the differences between
virus DNA burdens in different systems were tested by Students t
test.
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